Oxcarbazepine Tablet, Film Coated
Product Images NDC 60429-061

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 60429-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 061 05lb

Label for Oxcarbazepine tablets, USP 150 mg, supplied in a package of 500 tablets. The film-coated oral tablets are manufactured by Golden State Medical Supply, Inc. The label includes the NDC number 60429-061-05 and storage instructions. It cautions that the product is prescription only (Rx only) and advises consulting the package insert for dosage information.*

FDA Label Image

60429 062 05lb

Label for OXCARBAZEPINE 300 mg oral film-coated tablets, manufactured by Golden State Medical Supply, Inc. The bottle contains 500 tablets. The label includes the NDC number 60429-062-05, dosage strength, quantity, and storage instructions. It also states 'Rx only' and provides a URL for the medication guide.*

FDA Label Image

60429 063 05lb

Label for OXCARBAZEPINE tablets, USP 600 mg in a 500-tablet pack. The film-coated oral tablets are manufactured by LGM Pharma Solutions, LLC and distributed by Golden State Medical Supply, Inc. The label includes NDC 60429-063-05, dosage warnings, storage instructions, and a barcode.*

FDA Label Image

Oxcarbazepine 01

Chemical structure diagram of the active ingredient oxcarbazepine, showing its molecular framework including a dibenzazepine core and functional groups.*

FDA Label Image

Oxcarbazepine 02

A line graph showing the exit rate over time in days from Day 2 to Day 11 in a clinical trial. Two treatment groups are represented: Oxcarbazepine (solid line) and Placebo (dotted line). The graph includes a log-rank test with a p-value of 0.0001, indicating statistical comparison between groups.*

FDA Label Image

Oxcarbazepine 03

A Kaplan-Meier curve chart comparing seizure rates over time from first dose to first seizure between treatment groups receiving Oxcarbazepine and placebo. The x-axis represents days from first dose to first seizure (0 to 140 days), and the y-axis shows seizure rate (0 to 1). The plot includes a log-rank test with p-value of 0.046.*

FDA Label Image

Oxcarbazepine 04

A survival curve chart displaying exit rates over time in days for two treatment groups labeled HIGH and LOW. The x-axis shows time to exit (days) from 0 to 130, and the y-axis shows exit rate from 0.0 to 1.0. A log-rank test p-value of 0.0001 is indicated, suggesting a statistically significant difference between the groups.*

FDA Label Image

Oxcarbazepine 05

A Kaplan-Meier curve depicting exit rates over time (days) for two treatment groups labeled HIGH and LOW. The X-axis represents time to exit in days, and the Y-axis shows the exit rate from 0 to 1. The LOW group shows a steeper increase in exit rate compared to the HIGH group. The graph includes a log-rank test p-value of 0.0001 indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.